Neuropsychiatric Symptoms Associated with Efavirenz: Prevalence, Correlates and Management. A Neurobehavioral Review
José A. Muñoz-Moreno 1, Carmina R. Fumaz 1, Maria J. Ferrer 1, Marian González-García 1, José Moltó 1, Eugenia Negredo 2
1 NULL; 2 Universitat de Vic - Universitat Central de Catalunya, Vic; Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Barcelona. Spain
*Correspondence: Carmina R. Fumaz, Email not available
Abstract
The non-nucleoside analog reverse transcriptase inhibitor efavirenz is one of the most common componentsof HAART. Neuropsychiatric symptoms are frequently reported in patients taking efavirenzbasedregimens. These symptoms are usually transient, although they can sometimes persist for up totwo years after initiation of treatment. This review describes in detail the most common neuropsychiatricsymptoms related to efavirenz, outlines relevant and recent findings on this agent, and suggestspossible interventions based on neurobehavioral results. Different recommendations on the assessmentof efavirenz-related adverse events are also provided.
